Executive interview – Silence Therapeutics

Published on 18 July 2019
 

In this interview with David Horn Solomon, CEO of Silence Therapeutics, he discusses today’s announcement of a licensing and collaboration agreement with Mallinckrodt Pharmaceuticals to develop and commercialise RNAi drugs.

Share this with friends and colleagues